Development of next-generation treatment for allergies: targeted glycan-allergen immunotherapy
The TARGIT project will develop a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma effectively and life-long. The vaccine is based on unique glycans, covalently linked to clinically relevant grass pollen derived peptides. We will generate Proof-of-Concept for the product, entering clinical testing with the large pharma partner Allergopharma directly after this project, as well as for the core technology providing direct spin-off towards other allergens.
2 707 990.00€
Pharmaceutical Products / Drugs